IMCR
Immunocore Holdings plc
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeImmunocore's flagship KIMMTRAK revenue growth has decelerated with Q3 2026 results significantly missing consensus (revenue $102.2M vs. $152.1M expected, EPS miss of $0.11), driven by prior-period wholesaler stocking and timing factors. The company faces multiple headwinds: key Phase 3 TEBE-AM melanoma trial data pushed back to Q2 2027 (from late 2026), R&D leadership departure in early 2026, and a cascade of analyst downgrades/price target cuts in November 2026 reflecting diminished confidence.
Red flags
- •Q3 2026 revenue missed consensus by 33% ($102.2M vs. $152.1M expected)
- •EPS miss of $0.11 against consensus estimate
- •TEBE-AM Phase 3 topline data delayed from late 2026 to Q2 2027
- •Head of R&D David Berman resigned; company opted for restructure rather than direct replacement, signaling potential internal challenges
- •Multiple analyst downgrades/price target cuts in November 2026 (Zacks downgrade to 'strong sell'; Morgan Stanley PT cut from $43 to $42)
- •Moderating revenue growth guidance issued for 2026, suggesting deceleration ahead
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).